---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-042747"
form_type: "8-K"
ticker: "BIOA"
cik: "0001709941"
company_name: "BioAge Labs, Inc."
filed_at: "2025-03-20T23:59:59+00:00"
generated_at: "2026-05-24T10:24:40.165756+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BioAge Labs FY2024 net loss $71.1M; advances NLRP3 inhibitor BGE-102; discontinues azelaprag

## Summary
- Net loss of $71.1M ($6.63/share) for FY2024; cash $354.3M expected to fund operations through 2029.
- Discontinued azelaprag Phase 2 STRIDES trial due to unexpected liver transaminitis; continuing next-generation APJ agonists.
- Nominated BGE-102, an oral brain-penetrant NLRP3 inhibitor; Phase 1 SAD data expected 2H25, MAD data 1H26.
- New collaborations: Novartis (up to $20M upfront, $530M milestones) and Lilly (antibody discovery for metabolic aging targets).
- R&D expenses $59.0M (up 74% YoY); G&A $19.2M (up 32% YoY).

## SEC filing metadata
- accession: 0000950170-25-042747
- form_type: 8-K
- ticker: BIOA
- cik: 0001709941
- company_name: BioAge Labs, Inc.
- filed_at: 2025-03-20T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1709941/000095017025042747/0000950170-25-042747-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1709941/000095017025042747/bioa-20250320.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-042747
- JSON: https://secwatch.observer/filing/0000950170-25-042747.json
- Plain text: https://secwatch.observer/filing/0000950170-25-042747.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.